ストックスクリーナーアプリを入手
82.56
8.69%
-7.86
アフターアワーズ：
82.56
前日終値:
$90.42
開ける：
$89.67
24時間の取引高:
58,791
Relative Volume:
1.14
時価総額：
$509.39M
収益：
-
当期純損益:
$-7.12M
株価収益率:
-35.90
EPS:
-2.3
ネットキャッシュフロー:
$-6.82M
1週間 パフォーマンス:
-18.23%
1か月 パフォーマンス:
+44.84%
6か月 パフォーマンス:
+117.15%
1年 パフォーマンス:
+1,470%
1日の値動き範囲:
$81.53
$93.50
1週間の範囲:
$81.53
$104.00
52週間の値動き範囲:
$4.50
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
名前
Monopar Therapeutics Inc
セクター
電話
(847) 388-0349
住所
1000 SKOKIE BLVD SUITE 350, WILMETTE
MNPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
82.56 | 587.94M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-09-09 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | Oppenheimer | Outperform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-08-26 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-19 | 再開されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Piper Sandler | Overweight |
| 2024-10-11 | 開始されました | Rodman & Renshaw | Buy |
| 2021-01-28 | 開始されました | ROTH Capital | Buy |
すべてを表示
Monopar Therapeutics Inc (MNPR) 最新ニュース
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy - Yahoo
Multi factor analysis applied to Monopar Therapeutics Inc.Global Markets & Detailed Earnings Play Alerts - newser.com
Heatmap analysis for Monopar Therapeutics Inc. and competitorsWeekly Trade Summary & Detailed Earnings Play Strategies - newser.com
Monopar Therapeutics Inc. Announces Oral Presentation at AASLD 2025 for Phase 2 Study on Tiomolybdate Choline in Wilson Disease - Quiver Quantitative
Rapidly Improved Cu Balance: Monopar Phase 2 ALXN1840 Selected for Oral Presentation at AASLD Nov 9 - Stock Titan
Is Monopar Therapeutics Inc. (1IY0) stock overpriced at current multiplesGap Down & Low Risk Growth Stock Ideas - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated at Barclays - Defense World
Key metrics from Monopar Therapeutics Inc.’s quarterly dataTrade Analysis Summary & Safe Capital Growth Trade Ideas - newser.com
Is Monopar Therapeutics Inc. forming a reversal patternQuarterly Portfolio Review & Daily Profit Focused Screening - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Trading Up 16.3% After Analyst Upgrade - Defense World
Barclays Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation - Nasdaq
Barclays initiates Monopar Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
Is Monopar Therapeutics Inc. stock safe for conservative investorsWeekly Trade Recap & Free High Return Stock Watch Alerts - newser.com
Will Monopar Therapeutics Inc. stock recover faster than peersJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
MNPR: Barclays Initiates Coverage with Overweight Rating | MNPR Stock News - GuruFocus
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Monopar Therapeutics initiated with an Overweight at Barclays - TipRanks
Real time social sentiment graph for Monopar Therapeutics Inc.Weekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Raised to Strong-Buy at Jones Trading - Defense World
Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 12.3%Here's What Happened - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Upgraded to "Strong-Buy" at Jones Trading - MarketBeat
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted (NASDAQ:MNPR) - Seeking Alpha
Institutional scanner results for Monopar Therapeutics Inc.2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Monopar Therapeutics' (MNPR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential - TipRanks
What analysts say about Monopar Therapeutics Inc stockProtective Put Strategies & Low Risk Investment Trading - earlytimes.in
How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easingJuly 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
Raymond James Maintains Monopar Therapeutics (MNPR) Strong Buy Recommendation - Nasdaq
MNPR: Raymond James Raises Price Target to $142, Maintains Stron - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Hits New 1-Year HighTime to Buy? - MarketBeat
How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsWatch List & Fast Gaining Stock Strategy Reports - newser.com
Historical volatility pattern of Monopar Therapeutics Inc. visualizedTrade Entry Summary & Entry Point Strategy Guides - newser.com
Will Monopar Therapeutics Inc. (1IY0) stock beat Nasdaq index returnsTrade Risk Summary & Long-Term Safe Investment Ideas - newser.com
Risk adjusted return profile for Monopar Therapeutics Inc. analyzedJuly 2025 Big Picture & High Return Stock Watch Alerts - newser.com
Can trapped investors hope for a rebound in Monopar Therapeutics Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Using portfolio simulators with Monopar Therapeutics Inc. includedJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsGlobal Markets & Community Shared Stock Ideas - newser.com
Monopar Therapeutics Inc (MNPR) 財務データ
収益
当期純利益
現金流量
EPS
Monopar Therapeutics Inc (MNPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
2.96%
0.09%
大文字化:
|
ボリューム (24 時間):